Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AstraZeneca stock in Canada | $56.8

Own AstraZeneca shares in just a few minutes.

AstraZeneca PLC
NASDAQ: AZN - USD
DRUG MANUFACTURERS-GENERAL
$57.64
+$0.83 (+1.46%)

AstraZeneca is a drug manufacturers-general business based in the US. AstraZeneca stocks (AZN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $56.81 – an increase of 0.05% over the previous week. AstraZeneca employs 76,100 staff and has a trailing 12-month revenue of around $27.6 billion.

How to buy AstraZeneca stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AZN in this case.
  5. Research AstraZeneca stocks. The platform should provide the latest information available.
  6. Buy your AstraZeneca stocks. It's that simple.

How has Coronavirus impacted AstraZeneca's stock price?

Since the stock market crash in March caused by coronavirus, AstraZeneca's stock price has had significant positive movement.

Its last market close was $56.8, which is 11.67% up on its pre-crash value of $50.17 and 57.12% up on the lowest point reached during the March crash when the stocks fell as low as $36.15.

If you had bought $1,000 worth of AstraZeneca stocks at the start of February 2020, those stocks would have been worth $799.26 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,170.65.

AstraZeneca stock price

Use our graph to track the performance of AZN stocks over time.

AstraZeneca stocks at a glance

Information last updated 2021-07-28.
Latest market close$56.8
52-week range$46.48 - $60.93
50-day moving average $58.654
200-day moving average $53.4704
Wall St. target price$65.47
PE ratio 37.486
Dividend yield $2.8 (4.87%)
Earnings per share (TTM) $1.5155

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy AstraZeneca stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

AstraZeneca price performance over time

Historical closes compared with the last close of $56.8

1 month (2021-06-30) -5.18%
3 months (2021-04-30) 7.03%

Is AstraZeneca under- or over-valued?

Valuing AstraZeneca stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AstraZeneca's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AstraZeneca's P/E ratio

AstraZeneca's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, AstraZeneca stocks trade at around 37x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stocks or simply that they're over-valued.

AstraZeneca's PEG ratio

AstraZeneca's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4777. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

AstraZeneca's EBITDA

AstraZeneca's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$6.7 billion.

The EBITDA is a measure of a AstraZeneca's overall financial performance and is widely used to measure a its profitability.

AstraZeneca financials

Revenue TTM USD$27.6 billion
Operating margin TTM 14.85%
Gross profit TTM USD$21.4 billion
Return on assets TTM 4.19%
Return on equity TTM 29.67%
Profit margin 14.42%
Book value $5.499
Market capitalisation USD$176.8 billion

TTM: trailing 12 months

How to short and sell AstraZeneca stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "AZN.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 142.9 million AstraZeneca stocks held short by investors – that's known as AstraZeneca's "short interest". This figure is 4.3% up from 136.9 million last month.

There are a few different ways that this level of interest in shorting AstraZeneca stocks can be evaluated.

AstraZeneca's "short interest ratio" (SIR)

AstraZeneca's "short interest ratio" (SIR) is the quantity of AstraZeneca stocks currently shorted divided by the average quantity of AstraZeneca stocks traded daily (recently around 8.3 million). AstraZeneca's SIR currently stands at 17.15. In other words for every 100,000 AstraZeneca stocks traded daily on the market, roughly 17150 stocks are currently held short.

However AstraZeneca's short interest can also be evaluated against the total number of AstraZeneca stocks, or, against the total number of tradable AstraZeneca stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AstraZeneca's short interest could be expressed as 0.05% of the outstanding stocks (for every 100,000 AstraZeneca stocks in existence, roughly 50 stocks are currently held short) or 0.0546% of the tradable stocks (for every 100,000 tradable AstraZeneca stocks, roughly 55 stocks are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the stock price and a discouraging interest in betting against AstraZeneca.

Find out more about how you can short AstraZeneca stock.

AstraZeneca stock dividends

61%

Dividend payout ratio: 60.74% of net profits

Recently AstraZeneca has paid out, on average, around 60.74% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.47% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AstraZeneca shareholders could enjoy a 2.47% return on their shares, in the form of dividend payments. In AstraZeneca's case, that would currently equate to about $2.8 per share.

AstraZeneca's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

AstraZeneca's most recent dividend payout was on 29 March 2021. The latest dividend was paid out to all shareholders who bought their stocks by 25 February 2021 (the "ex-dividend date").

Have AstraZeneca stocks ever split?

AstraZeneca stocks were split on a 2:1 basis on 27 July 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your AstraZeneca stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for AstraZeneca stocks which in turn could have impacted AstraZeneca's stock price.

AstraZeneca stock price volatility

Over the last 12 months, AstraZeneca's stocks have ranged in value from as little as $46.48 up to $60.93. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while AstraZeneca's is 0.242. This would suggest that AstraZeneca's stocks are less volatile than average (for this exchange).

AstraZeneca overview

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site